ABSTRACT The secretion of plasminogen activators has been implicated in the controlled extracellular proteolysis that accompanies cell migration and tissue remodeling. We found that the human plasminogen activator urokinase (Uk) (Mr 55,000 form) binds rapidly, specifically, and with high affinity to fresh human blood monocytes and to cells of the monocyte line U937. Upon binding, Mr 55,000 Uk was observed to confer high plasminogen activator activity to the cells. Binding of the enzyme did not require a functional catalytic site (located on the B chain of the protein) but did require the noncatalytic A chain of Mr 55,000 Uk, since P/r 33,000 Uk did not bind. These results demonstrate the presence of a membrane receptor for Uk on monocytes and show a hitherto unknown function for the A chain of Uk: binding of secreted enzyme to its receptor results in Uk acting as a membrane protease. This localizes plasminogen activation near the cell surface, an optimal site to facilitate cell migration.
Various physiological and pathological processes, e.g., organogenesis during embryonic development, invasive and metastatic spreading of malignant tumors, and inflammatory reactions, require that certain cell types transgress the normal anatomical boundaries of tissues and migrate in and out of different body compartments. To allow such cellular migrations, mechanisms that provide for the focal degradation of components of the extracellular matrix must be available. Although the enzymatic basis for such degradation is not completely understood, several lines of evidence have suggested that extracellular proteolysis catalyzed by the secretion of plasminogen activators may play an important part in the degradative events necessary for migration of cells in tissues (24) .
The plasminogen activator urokinase (Uk),~ originally identified in human urine as an activator of the fibrinolytic system (27) , is a serine protease of tryptic specificity; it converts plasminogen, a zymogen, into plasmin, a neutral protease of broad specificity. Active human Uk consists of two polypeptide chains linked by a disulfide bond, and exists in a high molecular weight (Mr 55,000) and a low molecular weight (Mr 33,000) form; the latter is a proteolytic product of Mr 55,000 Uk lacking most of the A chain but retaining the Abbreviations used in this paper: AT-BSA, acid-treated BSA; DFP, diisopropylfluorophosphate; EGF, epidermal growth factor; FBS, fetal bovine serum: TA, tissue activator: Uk, urokinase.
active site-containing B chain (10) . It is now well established that a variety of cell types synthesize and secrete Uk-type plasminogen activators (9) ; these include cells endowed with migratory and invasive properties, such as monocytes-macrophages (34) , polymorphonuclear leukocytes (37) , and implanting trophoblast (30) , and cells derived from malignant tumors (19).
We describe here the specific binding of Mr 55,000 Uk to the surface of U937 cells, a monocyte-like human cell line (31) , and to freshly prepared human peripheral blood monocytes. This interaction provides a means by which Uk-producing cells can express both a secreted and a membraneassociated form of the enzyme. Enzymatic activity of membrane-bound Uk is localized to the vicinity of the cell surface, where it can catalyze the focal lysis of extracellular substrates, and may thereby facilitate monocyte migration.
MATERIALS AND METHODS
Cell Culture: U937 cells were grown in RPMI 1640 (Gibco Laboratoties, Grand Island, NY) supplemented with 5% fetal bovine serum (FBS) (Gibco Laboratories), and cultures were split V3 every 4 d.
Monocyte-entiched cultures were prepared from FicolI-Hypaque-purified human peripheral blood mononuclear cells (3) . Mononuclear cells were plated in fibrinogen-coated (10 #g/cm 2) Nunc (Bio AG, Basel, Switzerland) 24-well tissue culture plates (3 x 106 cells in 1 ml RPMI 1640 with 10% FBS that had been heated for 30 min at 56"C [HI-FBS]). 5 h later the wells were washed twice vigorously with RPMI 1640, and the cultures were incubated further for 16 h in RPMI 1640 with 10% HI-FBS.
Binding Studies: U937 cells were collected by centrifugation, washed twice in RPMI 1640, and resuspended at 1 x 106 cells/ml in RPMI 1640 containing 1 mg/ml acid-treated (17) BSA (A-7638, Sigma Chemical Co, St Louis, MO) (AT-BSA). Aliquots of 0.3 ml were distributed to Falcon No. 2058 tubes (Falcon Labware, Div., of Becton, Dickinson & Co., Oxnard, CA) and incubated as indicated. At the end of the incubation, the cultures were centrifuged (500 g, 5 min, 4"C) and the medium was collected and mixed with an equal volume of 2 x electrophoresis sample buffer (0.1 M Tris-Cl, pH 6.8, with 2% SDS and 20% glycerol). For the experiment of Fig. I , cells were washed three times with PBS + 1 mg/ml AT-BSA, resuspended in 0.15 ml PBS + AT-BSA, and mixed with an equal volume of 2 x electrophoresis sample buffer. For all other experiments, cells were resuspended in PBS + 3 mg/ml AT-BSA, spun through a layer of 5% sucrose and 2.5 mg/ml AT-BSA in PBS (800 g, 5 min, 4"C), and finally lysed in 50 gl 1 x electrophoresis sample buffer.
The monocyte cultures were washed four times with RPMI 1640 and incubated with J251-Uk in RPMI 1640 + 3 mg/ml AT-BSA. After incubation, the cultures were washed five times with PBS + 3 mg/ml AT-BSA, and the cells were lysed in I ml I M NaOH.
Radioactivity in the media and cell lysates was determined in a Beckman Gamma 310 counter (Beckman Instruments, Inc., Palo Alto, CA).
Gel Electrophoresis and Autoradiography: Samples (15 ul) were applied to 9% polyacrylamide slab gels in the presence of SDS (15, 34) ; after electrophoresis the gels were fixed and stained (0.2% Coomassie Blue in 30% methanol and 7.5% acetic acid), destained, and exposed to Kodak XAR-5 film for 16 h at -80"C using DuPont Cronex Par-Speed intensifying screens (E.I. DuPont de Nemours & Co., Newton, CT). Molecular weights were calculated from the position of markers (Pharmacia, Uppsala, Sweden; low molecular weight calibration kit) in the stained gels. Ficoll-Hypaque-purified mononuclear cells were plated in Falcon 35-mm tissue culture dishes (1.3 x l0 s cells in 1.5 ml RPMI 1640 with 10% HI-FBS). After 24 h of incubation, the cultures were washed four times with PBS, kept for 30 min at 37"C in RPMI 1640 + 1 mg/ml AT-BSA with or without added Uk, washed again three times with PBS, and overlayed with the casein-agarplasminogen medium.
Photographs were taken using dark-ground illumination. The dark plaques represent zones of casein lysis surrounding cells or groups of cells; lysis was not observed when plasminogen was omitted from the assay mixtures. 55 ,000 Uk (high molecular weight) was obtained from the Green Cross Corporation (Osaka, Japan) and '251-labeled using lodogen (Pierce Chemical Co, Rockford, IL) and Na-t251 (Amersham Ltd., Amersham, England) as described (1) , except that spun Sephadex G-50 (Pharmacia, Uppsala, Sweden) columns (18) were used to separate the protein from unreacted ~251. Mr 55,000 J251-Uk had a specific activity of-1.9 x 10 7 cpm//~g and was at least 80% enzymatically active (8) . Mr 33,000 Uk was the generous gift of Serono (Denens, Switzerland), and was ~Z~l-labeled as described for M, 55,000 Uk; Mr 33,000 Jz~i-Uk had a specific activity of ~1 x 107 cpm/ ~g, showed a single band of radioactivity with an apparent Mr of 33,000 after SDS PAGE, and was at least 80% enzymatically active.
Preparation of Reagents: M,
3'/, 55,000 and 33,000 unlabeled and ~2~l-labeled Uk were reacted with diisopropylfluorophosphate (DFP, Merck AG, Darmstadt, Federal Republic of Germany) in 0.5 M NaPO4, pH 7.4, by two additions of 10 mM DFP, for a total of I h at 20"C; enzymatic assays (8) of DFP-Uks showed that the enzymes had been inactivated by >95%.
Plasminogen was purified from human plasma by lysine-Sepharose (Pharmacia) affinity chromatography (6) . Plasmin was prepared as described (8) , and reacted with DFP as described for Uk. Murine epidermal growth factor (EGF) (culture grade) was from Collaborative Research Inc., (Lexington, MA), bovine insulin and human thrombin from Sigma Chemical Co., and human Factor Xa from Boehringer GmbH (Mannheim, Federal Republic of Germany). Human tissue activator (TA), purified from culture medium of HeLa cells, was the kind gift of Dr. W.-D. Schleuning and was I~I-labeled as described for Uk; 1251-TA had a specific activity of ~4 x 10 ~ cpm/#g, showed a predominant M, 75,000 radioactive band after SDS PAGE, and in contrast to the unlabeled enzyme, was catalytically inactive (8) . Rabbit antibodies to human urinary Uk were also generously provided by Dr W.-D. Schleuning (39); IgG were prepared by Protein A-Sepharose affinity chromatography (l 2).
RESULTS
The plasminogen activator secreted by human monocytesmacrophages and U937 cells is electrophoretically and immunologically identical to Mr 55,000 Uk (34) . To investigate the fate of Uk after secretion, we added ~2SI-labeled M~ 55,000 enzyme to U937 cells in culture. Cells and media were collected after 30 min of incubation at 37"C, and the cellassociated radioactivity was determined; the samples were also subjected to SDS PAGE under nonreducing conditions, and the gel was analyzed by autoradiography ( Fig. 1) . A substantial fraction (13.2 __. 0.1%) of the total radioactivity added to the cultures was associated with the cells and migrated with an apparent Mr of 55,000 (lane 2); in the presence of a 60-fold excess of unlabeled Mr 55,000 Uk, only 1.1 + 0.2% of the added radioactivity was cell associated (lane 4). Radioactivity remaining in the medium was quantitatively recovered as two major bands (lane I): an Mr 55,000 band, corresponding to the added 125I-Uk, and an M~ 94,000 band, corresponding to a covalent complex formed between Uk and a plasminogen activator-specific inhibitor secreted by U937 cells (34) ; this complex was not observed in the presence of excess unlabeled Uk (lane 3), the secreted inhibitor being saturated under these conditions. Cellular binding of ~25I-Uk showed only little temperature dependence: after 60 min of . Culture media and cell lysates were prepared and subjected to SDS PAGE followed by autoradiography. . Both ~2sl-Uk and DFP-~ZsI-Uk had the same specific activity (1.9 x 10 e cpm/ug). Cell lysates were prepared and subjected to SDS PAGE followed by autoradiography. Cell-bound usI-Uk represented 9.7 and 10.4% of the total radioactivity in cultures A1 and A2, 0.2 and 0.2'/o in B1 and B2, 11.4 and 11.7% in C1 and C2, and 0.2 and 0.1% in D1 and D2. incubation, 15.5 +_. 0.6% of the added t25I-Uk was cell associated at 37"C, and 12.3 ___ 0.3% at 0*C, indicating that endocytosis of the enzyme was probably not involved. These results suggested the existence of a saturable binding site for free 125I-Uk on the surface of U937 cells, and further experiments were carried out to characterize this interaction.
To investigate the contribution of the enzyme's catalytic site on the cellular binding of Uk, we reacted Mr 55,000 ~25I-Uk with DFP, an inhibitor ofserine esterases that irreversibly phosphorylates their active site. DFP-inactivated Mr 55,000 ~25I-Uk bound to U937 cells as effectively as the active enzyme (Fig. 2, lanes in A and C) , and this binding was also completely prevented in the presence of an excess of unlabeled Mr 55,000 Uk (Fig. 2, lanes in B and D) , or Mr 55,000 DFP-Uk (Table  I) . We concluded that enzymatic activity was not necessary for cellular binding of Uk, and that the catalytic site was probably not involved in this binding. Since DFP-~25I-Uk does not form a covalent complex with the U937-produced plasminogen activator-specific inhibitor, ~25I-Uk binding to U937 cells did not appear to be a consequence of covalent complex formation with this ligand. Nevertheless, to avoid the influence of possible secondary interactions between bound Uk and this ligand (such interactions being presumably responsible for the Mr 94,000 radioactive band associated with the cells after longer incubations with Mr 55,000 12sI-Uk [compare Fig. 1, lane 2 , and the lanes in Fig. 2A]) , we chose to carry out the following experiments using DFP-inactivated ~25I-Uk.
Cellular binding of M~ 55,000 DFP-t25I-Uk was fast, halfmaximal specific binding being achieved in <7 min at 20"C (Fig. 3A) . We also determined the amount of enzyme bound in the presence of increasing concentrations of Mr 55,000 DFP-t25I-Uk (Fig. 3B) . By Scatchard analysis of these data (Fig. 3 C) , we estimated the number of binding sites per U937 cell at approximately 60,000; the Kd of the interaction was calculated to be on the order of 4 x 10 -~° M. UK is synthesized and secreted as a one-chain, Mr 55,000, zymogen (21, 38) . Limited proteolysis by plasmin can convert this proUk into the two-chain, Mr 55,000, active enzyme (21, 38) , composed ofa 158 amino acid A chain and a 253 amino acid B chain, linked by a disulfide bond (l 1). This Uk form predominates in urine (8) . An Mr 33,000 form is also found in urine and cell culture media; it is composed of an intact B chain and a "mini" A chain consisting of the C-terminal 21 amino acids of the A chain (10, 29) . We have analyzed the binding of Mr 33,000 DFP-Uk to U937 cells (Table I) : we did not detect any specific binding of the ~zSI-labeled protein; in addition, using a nearly 100-fold molar excess of Mr 33,000 DFP-Uk, we found no inhibition of binding of Mr 55,000 DFP-~25I-Uk. These results indicate that Uk binding to U937 cells is a property of the M~ 55,000 form of the enzyme. Since Mr 33,000 Uk differs from Mr 55,000 Uk only by the absence of most of the enzyme's A chain (10), the cellular binding of Uk requires the presence of determinants of the intact A chain. (Table III) ; Mr 33,000 DFP-Uk did not bind to these cells (data not shown), nor did it prevent the binding of Mr 55,000 Uk. Binding is therefore not restricted to the monocyte-like U937 cell line. To visualize Uk bound to cultured monocytes, we used antibodies raised against the human enzyme. Indirect immunofluorescence did not reveal specific staining of untreated cells (Fig. 4A) , whereas 70% of cells that had been exposed to Mr 55,000 Uk were positive (Fig. 4B) ; binding of Mr 55,000 Uk can thus be demonstrated on most cultured monocytes-macrophages, and it is therefore not the property of a subpopulation or a contaminant in our cultures.
Since the cellular binding of Uk does not require a functional catalytic site, the bound enzyme may be active, and Uk secretion followed by binding to a high-affinity cellular site could result in Uk functioning in part as a cell-bound The experimental protocol is the same as for Table I . Percent inhibition was (alculated relative to controls containing Mr 55,000 DFP-I:SI-Uk (3 x 10 -'° M) added to the cells in the absence of competitors; under these conditions bound counts per minute represented 11.9 _+ 0.8% of total counts per minute added to the cultures. enzyme. To examine the validity of this hypothesis, we incubated U937 cells and monocytes with M, 55,000 or 33,000 Uk, washed the cells, and analyzed their plasminogen activator activity by the casein-agar overlay procedure (Fig. 5) . After incubation, proteolytic plaques surrounded a few of the U937 cells that had not been exposed to exogenous Uk (Fig. 5A ); these were due to the cellular synthesis and secretion of Uk. U937 cells that had been exposed to Mr 55,000 Uk produced many more plaques (Fig. 5 B) . These were due to the enzymatic activity of the exogenously added Uk, and not to increased Uk synthesis by treated cells, since cycloheximide (5 ~g/ml) did not prevent the increase in plasminogen activator activity after exposure to Mr 55,000 Uk, and since cells that had bound Mr 55,000 DFP-inactivated Uk did not produce more plaques than did control cells (data not shown). Finally, addition of Mr 33,000 Uk did not increase the proteolytic activity of U937 cells (Fig. 5 C) . Similar results were obtained with human monocytes: no lysis was observed in control cultures (Fig. 5A ) or in cultures that had been exposed to Mr 33,000 Uk (Fig. 5 C) , whereas Mr 55,000 Uk-treated cultures produced many proteolytic plaques ( Fig. 5 B) ; phasecontrast microscopy confirmed that the zones of lysis surrounded monocytes-macrophages. We concluded that cellbound Mr 55,000 Uk remains at least in part enzymatically active, and can thereby catalyze plasmin-mediated proteolysis around monocytes and U937 cells.
DISCUSSION
The cellular binding of the plasminogen activator Uk (Mr 55,000 form) provides a mechanism by which the enzyme can function not only as a secreted protease, diffusing away from its site of synthesis, but also in a membrane-associated form, catalyzing focalized plasmin formation and thereby high proteolytic activity in the close environment of the cell. Although the role of plasminogen activator in the biology of mononuclear phagocytes remains a matter of conjecture, enzyme production is thought to be related to the migratory properties of these cells (35) . In this context, a membranebound plasminogen activator is optimally located to generate proteolytic activity along the path of monocyte migration. In addition, membrane-bound Uk may be less susceptible to the protease inhibitors present in the extracellular fluid (4, 5) . Plasminogen activation has been postulated to be essential for the migratory and invasive properties of other Uk-producing cells, such as implanting murine trophoblasts (30) or malignant cells (19, 22) ; similar Uk-binding sites may thus exist on the surface of these cells as well. Binding of Mr 55,000 Uk to human monocytes and U937 cells may be related to the fact that these cells themselves produce Uk (34) . We propose that during or following secretion, at least some of the (pro?)enzyme binds to the cell surface. In this respect, it is of interest to note that murine macrophages, which synthesize a Uk-type enzyme (in preparation), express a membrane-associated form of plasminogen activator (5, 16, 28) . The interaction described here suggests that this membrane-associated form of the enzyme is due to the binding of secreted Uk to a high-affinity cell membrane receptor, rather than to the synthesis and membrane insertion of a distinct species of plasminogen activator. It should also be recalled that Uk and proUk are present in human plasma (32, 39) , at a concentration (1-2 x 10-~°M) which is on the order of the/~ value determined in this paper for Mr 55,000 Uk binding to U937 cells. One may thus speculate that cells can bind circulating enzyme, or enzyme produced by neighboring cells in the environment of a tissue.
The Mr 33,000 form of Uk did not bind to the cells studied; it differs from Mr 55,000 Uk by the absence of the first 135 amino acids of the 158 amino-acid A chain. This indicates that determinants of the A chain are necessary for binding to occur, although at this time it cannot be taken to imply that the A chain itself does bind to the cellular receptor. To further characterize the cellular binding of Mr 55,000 Uk, it will be of interest to evaluate the binding of proUk, and of various fragments derived from the A chain of the enzyme. In any event, the requirement for the presence of an intact A chain for cellular binding of Uk provides a novel function for this domain of the molecule.
We did not detect any significant competition for binding of Mr 55,000 Uk by other proteins with homologies to the A chain of the enzyme, nor by thrombin, suggesting that the binding site is specific for Uk. Binding of both thrombin and a functional prothrombinase complex (consisting of factors Va and Xa) to human monocytes have also recently been described (7, 33) . Fibrin formation as well as fibrinolysis can thus be catalyzed at or near the surface of monocytes-macrophages; membrane binding sites for these seemingly antagonistic reactions appear to be different, and regulation of their expression may control the overall deposition and removal of fibrin around these cells, in particular within inflammatory lesions.
The cellular binding of Mr 55,000 Uk contrasts with the absence of interaction between the other human plasminogen activator, namely TA, and the cells studied in this work. We suggest that Mr 55,000 Uk is a form of plasminogen activator with an affinity for the cell surface, where it catalyzes plasmin formation in the close environment of the ceil, in the same way that TA represents a form of plasminogen activator with an affinity for fibrin clots where it catalyzes a high plasminmediated thrombolytic activity (20) . The determinants that direct these specific extracellular localizations appear to reside in the A chains of both enzymes. The recently described adsorption of TA to cultured fibroblasts (13) suggests that this form of plasminogen activator also can become cell associated. However, in contrast with the cellular binding of Uk described here, binding of TA was due to the formation of an SDS-resistant complex between the enzyme and a cellular ligand; furthermore, TA adsorption to fibroblasts was slow as compared with that of Uk to U937 ceils, and appeared to be involved in the clearance of the enzyme.
Finally, the interaction of Uk with U937 cells and monocytes could be considered as that of a hormone with its membrane receptor. The region within the A chain of Mr 55,000 Uk which is homologous to murine EGF has been described as a "growth factor domain" (11). Our studies show that EGF does not compete for the Uk binding site; nevertheless, we intend to search for possible "trophic" effects of Mr 55,000 Uk on monocytes and other cells. Increased levels of Uk have been observed in malignant tumors (19), and autocrine effects (14) may be responsible for some aspects of the malignant phenotype.
